MedTrace Logo

Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

NCT01922102 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 457

Last updated 2019-06-24

Study results available
· View outcomes & findings →

Summary

This study was designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia (PM)

Conditions

  • Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

Interventions

DRUG

Ranibizumab 0.5mg

0.5 mg ranibizumab (intravitreal injections)

DRUG

Ranibizumab 0.5 mg

0.5 mg ranibizumab (intravitreal injections)

DRUG

Verteporfin PDT

Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-11
Primary Completion
2016-09-14
Completion
2016-09-14

Countries

  • China
  • Hong Kong
  • India
  • Philippines
  • South Korea
  • Thailand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01922102 on ClinicalTrials.gov